C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 9/22 (2006.01) A01K 67/027 (2006.01) A61K 31/7088 (2006.01) A61K 38/46 (2006.01) A61K 39/395 (2006.01) A61K 45/00 (2006.01) A61K 48/00 (2006.01) A61P 35/00 (2006.01) C07H 21/00 (2006.01) C07K 16/28 (2006.01) C12N 5/00 (2006.01) G01N 33/50 (2006.01)
Patent
CA 2445611
Method of treating or diagnosing cancers involving P-cadherin expression are provided using ligands that target P-cadherin, especially human anti-P- cadherin antibodies. Also provided are screens for identifying anti-P-cadherin antibodies having therapeutic activity.
Cette invention se rapporte à un procédé pour traiter ou diagnostiquer des cancers impliquant l'expression de P-cadhérine, en utilisant des ligands qui ciblent la P-cadhérine, en particulier des anticorps anti-P-cadhérine humains. Cette invention concerne également des criblages pour identifier des anticorps anti-P-cadhérine ayant une action thérapeutique.
Escobedo Jaime
Goodson Robert
Jefferson Anne B.
Klinger Julie
Qi Weimin
Borden Ladner Gervais Llp
Chiron Corporation
Novartis Vaccines And Diagnostics Inc.
LandOfFree
P-cadherin as a target for anti-cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with P-cadherin as a target for anti-cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P-cadherin as a target for anti-cancer therapy will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1916705